Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are...

Full description

Bibliographic Details
Main Authors: Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, Takechiyo Yamada
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Medicina
Subjects:
head and neck squamous cell carcinoma
cetuximab
paclitaxel
immune checkpoint inhibitor
chemotherapy
Online Access:https://www.mdpi.com/1648-9144/57/11/1151

Similar Items

Similar Items